Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

Food for Thought: On Eating & Inflammation in Rheumatic Disease

Susan Bernstein  |  November 14, 2020

Certain nutrients or dietary patterns may affect inflammation and rheumatic disease risk in certain populations. Recommended nutrients include omega-3 fatty acids found in fish, poultry or nuts. Following a Mediterranean or standard Western diet may affect RA risk too.

A Close Look at Antibodies in RA

Carina Stanton  |  November 13, 2020

ACR CONVERGENCE 2020—Recent research findings suggest rheumatologists need to take a closer look at two gold standard autoantibodies used to diagnose seropositive rheumatoid arthritis (RA)—rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), according to Caroline Grönwall, PhD, and Miriam Shelef, MD, PhD, who discussed Antibodies in RA: Beyond Citrullination & Back to Rheumatoid Factor at…

Lupus Nephritis: New Decade, New Approaches

Thomas R. Collins  |  November 13, 2020

Experts say progress is being made on a variety of fronts in lupus nephritis. New data, for instance, shows that repeat biopsy beyond that used for diagnosis can help guide treatment and greatly reduce the flare rate. New treatments – including belimumab and the calcineurin inhibitors tacrolimus and voclosporin — have yielded improved response rates in LN…

Can We Predict & Prevent Pregnancy Complications in Patients with Lupus & APS?

Thomas R. Collins  |  November 13, 2020

ACR CONVERGENCE 2020—New evidence, though derived from small numbers, suggest that treatment with the TNF-inhibitor certolizumab could help improve high-risk pregnancy outcomes in women with antiphospholipid syndrome (with or without systemic lupus erythematosus) and lupus anticoagulants, an expert said. In the Phase 2 IMPACT trial, which has already enrolled 27 women and is continuing to…

Racial Disparities in Rheumatology: RA, OA & Arthroplasty

Thomas R. Collins  |  November 13, 2020

ACR CONVERGENCE 2020—Evidence shows that African Americans have a higher burden of osteoarthritis, with lower use of conventional medications, and are less adherent to the medications they take. They also get arthroplasty procedures less often, and when they do have the procedures, they report greater pain, worse function and lower satisfaction with them. In RA…

FAST Results for Febuxostat Safety in Patients with Gout

Keri Losavio  |  November 12, 2020

ACR CONVERGENCE 2020—The results of a post-authorization study comparing the cardiovascular safety of febuxostat vs. allopurinol were presented in a late-breaking abstract session at the ACR’s fully virtual annual meeting on Monday, Nov. 9. Cardiologist Thomas MacDonald, MD, FRCP, MBChB, clinical professor (teaching and research) of molecular and clinical medicine, University of Dundee School of…

Lupus Immunology Trends Provide Insights for Rheumatologists

Vanessa Caceres  |  November 12, 2020

ACR CONVERGENCE 2020—With an understanding of the key causes that are behind immune abnormalities in systemic lupus erythematosus (SLE), rheumatologists gain insights into this disease. During the ACR Convergence session Immunology Update—The Decade in Review: 10 Steps to SLE, Chandra Mohan, MD, PhD, Hugh Roy and Lillie Cranz Cullen Endowed Professor, University of Houston, provided…

RA Patients with ILD & Liver Disease Present Treatment Challenges

Vanessa Caceres  |  November 12, 2020

ACR CONVERGENCE 2020—Patients with concurrent rheumatological arthritis (RA) and liver disease or interstitial lung disease or treatment-refractory rheumatoid arthritis pose treatment challenges, according to the panelists of the ACR Convergence 2020’s How I Treat Difficult RA: Panel Session. Each panelist discussed a difficult case and raised questions on how to best treat it. Joan M….

Newer Targets Pave the Way for Future Lupus Therapies

Vanessa Caceres  |  November 12, 2020

ACR CONVERGENCE 2020—Although rheumatologists have struggled with a lack of new therapies for systemic lupus erythematosus (SLE), recent positive trial results have brought renewed hope for more treatments. That was the theme of the ACR Convergence 2020 session, State of the Art: Lupus—The Future Is Now, led by Peggy Crow, MD, the Benjamin M. Cohen…

The New Guidance Subcommittee Gives ACR More Document Flexibility

Ruth Jessen Hickman, MD  |  November 12, 2020

The ACR publishes multiple types of documents to provide guidance for its members, but some potentially beneficial topics have not fit neatly into existing production pathways. To answer the need, the ACR has formed a Guidance Subcommittee to the Quality of Care (QOC) Committee. This will allow the ACR to adapt more nimbly, when appropriate,…

  • « Previous Page
  • 1
  • …
  • 74
  • 75
  • 76
  • 77
  • 78
  • …
  • 307
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences